UK Regulators, Industry Spar Over Drug Development Costs

British regulators are questioning whether the cost of drug development is unnecessarily high, in response to editorials in The Times of London warning of a potential manufacturing exodus. In an Aug. 30 opinion article, Jonathan Emms, Pfizer’s managing director in the UK, says the National Institute for Health and Care Excellence has created a regulatory environment that is stifling drug development.
International Pharmaceutical Regulatory Monitor